Payment overview · 2025
General Payments
$356.69
16 reported records · 8 companies
Healthcare provider profile · identity verified
Sergio Rene Gomez, MD
Allopathic & Osteopathic Physicians|Family Medicine · POMONA, CA · NPI 1689720112
Verified facts
What the public records show
CMS Open Payments records show Sergio Rene Gomez, MD received $356.69 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 59.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $211.13 | 59.2% | 8 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $35.60 | 10.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.38 | 7.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.22 | 5.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.74 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.18 | 4.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.79 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.65 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $356.69 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $151.37 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $59.76 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $35.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.38 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 230 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 315 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 347 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 182 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
230 | 46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
315 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
315 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
347 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
182 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1309 | 408 |
| Gabapentin | Gabapentin | 958 | 333 |
| Metformin Hcl | Metformin Hcl | 635 | 204 |
| Metoprolol Succinate | Metoprolol Succinate | 494 | 147 |
| Escitalopram Oxalate | Escitalopram Oxalate | 457 | 153 |
| Losartan Potassium | Losartan Potassium | 371 | 106 |
| Diclofenac Sodium | Diclofenac Sodium | 348 | 104 |
| Ozempic | Semaglutide | 347 | 48 |
| Omeprazole | Omeprazole | 346 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 94 |
| Jardiance | Empagliflozin | 315 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 103 |
| Mirtazapine | Mirtazapine | 261 | 78 |
| Eliquis | Apixaban | 244 | 39 |
| Alendronate Sodium | Alendronate Sodium | 234 | 77 |
| Spironolactone | Spironolactone | 233 | 87 |
| Farxiga | Dapagliflozin Propanediol | 230 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 207 | 60 |
| Allopurinol | Allopurinol | 191 | 63 |
| Benazepril Hcl | Benazepril Hcl | 187 | 59 |
| Entresto | Sacubitril/Valsartan | 185 | 31 |
| Rybelsus | Semaglutide | 182 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 181 | 36 |
| Ezetimibe | Ezetimibe | 177 | 60 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 176 | 79 |
| Carvedilol | Carvedilol | 172 | 53 |
| Lisinopril | Lisinopril | 168 | 50 |
| Prednisone | Prednisone | 160 | 40 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 149 | 41 |
| Simvastatin | Simvastatin | 148 | 42 |
| Naproxen | Naproxen | 127 | 53 |
| Trazodone Hcl | Trazodone Hcl | 124 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 42 |
| Januvia | Sitagliptin Phosphate | 110 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 28 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 87 | 35 |
| Alcohol Pads | Alcohol Antiseptic Pads | 84 | 47 |
| Finasteride | Finasteride | 67 | 24 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 62 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 54 |
| Azithromycin | Azithromycin | 59 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 58 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 13 |
| Donepezil Hcl | Donepezil Hcl | 54 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 18 |
| Glimepiride | Glimepiride | 52 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 51 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 13 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 46 | 21 |
| Methenamine Hippurate | Methenamine Hippurate | 45 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 13 |
| Clotrimazole | Clotrimazole | 43 | 24 |
| Memantine Hcl | Memantine Hcl | 43 | 12 |
| Methotrexate | Methotrexate Sodium | 42 | 12 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 41 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Acyclovir | Acyclovir | 38 | 24 |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | 11 |
| Atenolol | Atenolol | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 12 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Methenamine Mandelate | Methenamine Mandelate | 28 | 15 |
| Montelukast Sodium | Montelukast Sodium | 27 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Furosemide | Furosemide | 26 | 16 |
| Premarin | Estrogens, Conjugated | 26 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 16 |
| Folic Acid | Folic Acid | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Erythromycin | Erythromycin Base | 22 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Glipizide | Glipizide | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Prolia | Denosumab | 17 | 15 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $356.69 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, DUPIXENT, FARXIGA, JARDIANCE, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error